A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer

Prostate cancer is diagnosed in over 1 million men every year globally, yet current diagnostic modalities are inadequate for identification of significant cancer and more reliable early diagnostic biomarkers are necessary for improved clinical management of prostate cancer patients. MicroRNAs (miRNA...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2018-04, Vol.8 (1), p.6653-15, Article 6653
Main Authors: Matin, Farhana, Jeet, Varinder, Moya, Leire, Selth, Luke A., Chambers, Suzanne, Clements, Judith A., Batra, Jyotsna
Format: Article
Language:English
Subjects:
13/89
38
38/109
38/39
38/47
38/77
38/90
45/41
631/67/1059/602
631/67/2322
631/67/589/466
Biomarkers
Body fluids
Cell migration
Cell proliferation
Chromosome 3
Diagnosis
Humanities and Social Sciences
MicroRNAs
miRNA
multidisciplinary
Pathogenesis
Patients
Prostate cancer
Science
Science (multidisciplinary)
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate cancer is diagnosed in over 1 million men every year globally, yet current diagnostic modalities are inadequate for identification of significant cancer and more reliable early diagnostic biomarkers are necessary for improved clinical management of prostate cancer patients. MicroRNAs (miRNAs) modulate important cellular processes/pathways contributing to cancer and are stably present in body fluids. In this study we profiled 372 cancer-associated miRNAs in plasma collected before (~60% patients) and after/during commencement of treatment (~40% patients), from age-matched prostate cancer patients and healthy controls, and observed elevated levels of 4 miRNAs - miR-4289, miR-326, miR-152-3p and miR-98-5p, which were validated in an independent cohort. The miRNA panel was able to differentiate between prostate cancer patients and controls (AUC = 0.88). Analysis of published miRNA transcriptomic data from clinical samples demonstrated low expression of miR-152-3p in tumour compared to adjacent non-malignant tissues. Overexpression of miR-152-3p increased proliferation and migration of prostate cancer cells, suggesting a role for this miRNA in prostate cancer pathogenesis, a concept that was supported by pathway analysis of predicted miR-152-3p target genes. In summary, a four miRNA panel, including miR-152-3p which likely targets genes with key roles in prostate cancer pathogenesis, has the potential to improve early prostate cancer diagnosis.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-018-24424-w